Sylvia Herter

Schlieren, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Journal: Cancer research communications

Published: March 18, 2026

3D ex vivo platform for high-throughput immunotherapy screening in relapsed/refractory lymphoma patients.

3D ex vivo platform for high-throughput immunotherapy screening in relapsed/refractory lymphoma patients.

Journal: HemaSphere

Published: December 18, 2025

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial.

Journal: Nature medicine

Published: December 15, 2025

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Journal: Molecular cancer

Published: September 08, 2025

Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL.

Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed/refractory B-NHL.

Journal: Blood

Published: August 22, 2025

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Molecular Features of Response and Resistance to Glofitamab, a T-Cell Engager for treatment of Large B-Cell Lymphoma.

Journal: Blood advances

Published: April 21, 2025

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Journal: Blood advances

Published: April 21, 2025

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Journal: Blood

Published: February 20, 2025

Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESI.

Resolving the structural basis of therapeutic antibody function in cancer immunotherapy with RESI.

Journal: Nature communications

Published: December 13, 2024

Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody.

Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody.

Journal: Clinical and translational medicine

Published: July 29, 2024

Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation.

Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation.

Journal: eLife

Published: December 21, 2023

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Journal: Blood

Published: November 27, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026